| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2006-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f7d6ac21843c5109199929f1cfd3da6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_027bb74f8c5b60ce30e0f4c671da97e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42fc234d2319429970b1f736eb1b6f7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d78c7e76fe7327ff4d9ec145b9c75ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e61c83f4b5f68e9c76aa1d7d6866da72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d56126193dca8ebdcbcd37123a76315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc666e9f7b1d9930ece783fdbe59de57 |
| publicationDate |
2009-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009029367-A1 |
| titleOfInvention |
Polymorphisms in pon1 are associated with elevated alanine aminotransferase levels after ximelagatran or tacrine administration |
| abstract |
This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between certain SNPs in the PON1 gene and susceptibility to increased levels of alanine aminotransferase (ALAT) following ximelagatran or tacrine administration. Thus, this invention relates to methods for predicting susceptibility to elevated ALAT following ximelagatran or tacrine administration and to methods for administering a pharmaceutically useful anticoagulant drug to certain suitable patients. |
| priorityDate |
2005-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |